Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker

Journal of the National Cancer Institute

Volumn 105, Issue 14, 2013, Pages 1036-1042

  Sgroi, Dennis C ^a   Carney, Erin ^a   Zarrella, Elizabeth ^a   Steffel, Lauren ^a   Binns, Shemeica N ^a   Finkelstein, Dianne M ^a   Szymonifka, Jackie ^a   Bhan, Atul K ^a   Shepherd, Lois E ^b   Zhang, Yi ^c   Schnabel, Catherine A ^c   Erlander, Mark G ^c   Ingle, James N ^d   Porter, Peggy ^e   Muss, Hyman B ^f   Pritchard, Katherine I ^b,g   Tu, Dongsheng ^b   Rimm, David L ^h   Goss, Paul E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c BioTheranostics Inc   (United States)

^d MAYO CLINIC   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HOX PROTEIN; INTERLEUKIN 17; LETROZOLE; PLACEBO; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NITRILES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, INTERLEUKIN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84880515409     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt146     Document Type: Article

References (26)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
2. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802. (Pubitemid 37362955)
3. Jin H, Tu D, Zhao N, et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 2011;30:718-721.
4. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784-3796.
5. Carlson RW, Allred DC, Anderson BO, et al. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines, Breast Cancer. 2011 J Natl Compr Cancer Netw. 2011;9:136-222.
6. Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat. 2007;105(Suppl 1):45-53. (Pubitemid 47524799)
7. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55-65.
8. Cardoso F, Van't Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008;26:729-735. (Pubitemid 351264385)
9. Burstein HJ, Griggs JJ. Deep time: the long and the short of adjuvant endocrine therapy for breast cancer. J Clin Oncol. 2012;30:684-686
10. Goetz MP, Suman VJ, Ingle JN, et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006;12:2080-2087.
11. Ma XJ, Hilsenbeck SG, Wang W, et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006;24:4611-4619. (Pubitemid 46630959)
12. Ma XJ, Salunga R, Dahiya S, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008;14:2601-2608.
13. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5:607-616. (Pubitemid 38748922)
14. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446-1152.
15. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
16. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
17. Hothorn T, Bretz F, Westfall P: Simultaneous inference in general parametric models. Biom J. 2008;50:346-363
18. Langholz B, Borgan O. Estimation of absolute risk from nested case-control data. Biometrics. 1997;53:767-774. (Pubitemid 27262238)
19. Devlin TF, Weeks BJ. Spline functions for logistic regression modeling. Proceedings of the 11th Annual SAS Users Group International Conference. Cary, NC: SAS Institute; 1986:646-651
20. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271. (Pubitemid 41535367)
21. Dent SF, Gaspo R, Kissner M, et al. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat. 2011;126:295-310.
22. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556-562. (Pubitemid 351264348)
23. Verma S, Madarnas Y, Sehdev S, et al. Patient adherence to aromatase inhibitor treatment in the adjuvant setting. Curr Oncol. 2011;18(Suppl 1):S3-S9.
24. Myrick ME, Schmid SM, Kilic N, et al. Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer. Acta Oncol. 2011;51:247-253.
25. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26:1948-1955.
26. Goss PE, Muss HB, Ingle JN, et al. Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer. 2008;8:411-417.